VolitionRx Limited reported $1.4 million in revenue for the first half of 2026, up 112% year over year, as it advanced clinical programs, commercial partnerships and licensing discussions. Its Nu.Q® NETs assay, which measures nucleosomes associated with NETosis (a process linked to immune-system inflammation), was supported by a peer-reviewed study and an editorial in Critical Care Medicine showing predictive value for 28-day mortality and renal replacement therapy in sepsis and septic shock. Recruitment for the government-backed, approximately $7.3 million DETECSEPS program in France is expected to begin in September 2026. Volition also reported progress toward a finger-prick lateral-flow test for point-of-care sepsis assessment, plans a conditional reimbursement submission for Nu.Q® Cancer in France by the end of 2026, and submitted a feline lymphoma manuscript that could trigger an anticipated $5 million milestone payment after publication. The company transferred its Nu.Q® NETs assay to Sysmex Corporation's platform ahead of an anticipated broader agreement. Its Capture-Seq™ liquid-biopsy platform detected more than 95% of Stage I and II cancers with 95% specificity in a blinded validation cohort, supporting a stated annualized cancer-detection market opportunity of $23 billion. Volition said it is in active discussions, including technical evaluations, with more than a dozen diagnostic and liquid-biopsy companies.